Testing brentuximab and etoposide for T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding the drugs brentuximab and etoposide to standard chemotherapy improves treatment for people newly diagnosed with T-cell lymphoma. It aims to find a more effective first treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with a type of T-cell lymphoma (a cancer of certain immune cells).
- You do not have any active infections or chronic health problems that are getting worse.
- You are able to get out of bed and take care of yourself most of the day (ECOG performance status 0-2).
- You have not had another cancer in the last 5 years, except for easily treated cancers like some skin cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
This study looks at how well a combination drug treatment (brentuximab vedotin plus chemotherapy) works for patients with rare T-cell lymphomas in real-world clinical practice in Spain. It focuses on patients receiving this as their first treatment.
This trial tests whether giving a drug called brentuximab vedotin after a stem cell transplant can help keep your lymphoma in check and prevent it from coming back. It is for people with a specific type of lymphoma (mycosis fungoides) that has been hard to treat and who have recently had a transplant.
This trial tests a new combination of drugs for people with a type of lymphoma called EBV-positive DLBCL that has not been treated before. The goal is to see if adding brentuximab vedotin to the standard R-CHP chemotherapy can improve outcomes.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.